Related Experiment Video
Updated: Oct 8, 2025
13:36
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10.5K
Adenovirus vector-based vaccine for infectious diseases
Fuminori Sakurai1, Masashi Tachibana2, Hiroyuki Mizuguchi3
1Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Drug Metabolism and Pharmacokinetics
|January 2, 2022
Summary
Replication-incompetent adenovirus (Ad) vectors are promising for gene therapy and vaccines due to high efficiency and stability. This review explores Ad vector properties, immunity, and applications for infectious diseases like COVID-19.
Area of Science:
- Biotechnology
- Immunology
- Gene Therapy
Background:
- Replication-incompetent adenovirus (Ad) vectors offer high transduction efficiency, large transgene capacity, and high titer production.
- Ad vectors exhibit moderate innate immunogenicity and good thermostability, making them suitable for vaccine development.
- Current research highlights Ad vectors for preventing infectious diseases, including Ebola, AIDS, and COVID-19.
Purpose of the Study:
- To review the fundamental characteristics of Ad vectors.
- To discuss Ad vector-induced innate immunity and immune responses to transgene products.
- To explore novel Ad vector development and clinical applications for infectious disease vaccines.
Main Methods:
- Literature review of Ad vector properties and applications.
- Analysis of immune responses to Ad vectors and transgene products.
- Discussion of advancements in Ad vector technology for vaccine development.
Main Results:
- Ad vectors possess advantageous properties for gene delivery and vaccine applications.
- Understanding Ad vector-induced immunity is crucial for optimizing vaccine design.
- Novel Ad vectors are being developed to address limitations of current vaccine strategies.
Conclusions:
- Ad vectors show significant potential as vaccines against various infectious diseases, including COVID-19.
- Further development of Ad vectors is needed to overcome existing challenges and enhance clinical efficacy.
- Ad vectors represent a versatile platform for next-generation vaccines and gene therapies.
